Brokerages Downgrade Editas to 'Hold', Shares Slump 23%

Editas Medicine, a leading gene editing company, has seen a significant drop in its stock price, plummeting by 23% following downgrades from several brokerages. The company's shares are now trading at $1.41, a stark contrast to the average 12-month price target of $8.00 set by analysts. This discrepancy suggests a potential buying opportunity for investors, as the current price is 83.33% below the average target. Despite the recent slump, Editas Medicine's long-term prospects remain promising, with analysts maintaining a 'Buy' consensus rating. The company's strategic pivot towards in vivo gene editing and its progress in clinical trials, such as the RUBY trial for sickle cell disease, indicate a strong pipeline and potential for future growth. Investors should consider the current dip as a chance to accumulate shares at a discounted price, given the company's long-term potential and the positive outlook from analysts.